Gradientech at ESCMID Global 2025

Gradientech showcases new QuickMIC clinical data and innovations at ESCMID Global 2025

25 Mar 2025

The diagnostics company Gradientech announces the presentation of new study data from clinical, real-world evaluations with its QuickMIC^® system for ultra-rapid antibiotic susceptibility testing (AST) at ESCMID Global 2025 in Vienna, Austria, April 11th-15th.

ESCMID Global, organised by ESCMID - European Society of Clinical Microbiology and Infectious Diseases, is one of the most comprehensive and influential congresses in infectious diseases and microbiology, bringing together over 16,000 professionals worldwide.

Gradientech presents three abstracts, highlighting new clinical data from QuickMIC^® studies in both low and high-resistance settings, including results on rapid AST for patients with urosepsis and rapid AST results for cefiderocol - an antibiotic that has posed a challenge for traditional AST systems. An additional abstract by Padua University Hospital in Italy presents a comparison of the performance of QuickMIC and traditional AST testing.

“We are proud to have a significant number of QuickMIC studies being presented at ESCMID Global this year. In addition, we will showcase the latest version of the QuickMIC system with an integrated screen solution that will reduce the footprint to a minimum in our users’ labs. All this gives us a golden opportunity to highlight and show how QuickMIC, with precise MIC values, ultra-rapid test times, and a minimum footprin,t can advance AST diagnostics to the next level,” says Sara Thorslund, CEO and co-founder at Gradientech. “ESCMID Global is truly an international hub where leading experts, clinicians, and microbiologists gather to exchange valuable insights to advance the field.”